FindTrial
Sign In

IPN10200 placebo

DRUG4 trials

Sponsors

Ipsen Innovation, Ipsen

Conditions

Episodic Migraine Chronic MigraineModerate to Severe Upper Facial LinesTreatment of Moderate to Severe Upper Facial LinesUpper limb spasticity after stroke or traumatic brain injury

Phase 1

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
RecruitingNCT04821089
IpsenModerate to Severe Upper Facial Lines
Start: 2021-04-06End: 2027-03-05Target: 727Updated: 2025-12-31
An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the treatment of Adult Upper Limb Spasticity Followed by an Open-label Extension Period
RecruitingCTIS2023-507202-14-00
Ipsen InnovationUpper limb spasticity after stroke or traumatic brain injury
Start: 2021-04-29Target: 298Updated: 2026-01-19
A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults
RecruitingCTIS2024-512782-14-00
Ipsen InnovationTreatment of Moderate to Severe Upper Facial Lines
Start: 2024-03-20Target: 727Updated: 2025-10-29

Phase 2

A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults
Not yet recruitingCTIS2024-511101-28-00
Ipsen InnovationEpisodic Migraine Chronic Migraine
Target: 311Updated: 2025-09-17